The Global Thin Film Drug Manufacturing Market was valued at USD 6.4 billion in 2023 and is projected to grow with a compound annual growth rate (CAGR) of 9.0% from 2024 to 2032. Thin film drug manufacturing involves the design and production of thin films containing biochemical elements for pharmaceutical purposes, which can be administered sublingually, orally, or via transdermal methods. These advanced drug delivery systems offer precise dosage, improved patient compliance, ease of administration, and rapid onset of biological effects, making them especially beneficial for children and the elderly.
The increasing global elderly population, driven by improvements in healthcare facilities and a decline in birth rates, is a prominent contributor to the growth of the thin film drug manufacturing market. Thin film drug delivery systems are particularly advantageous for the elderly, as they reduce the risk of choking, ease swallowing difficulties, and improve the overall administration of drugs. The rise in investment in drug delivery technologies is another significant factor augmenting the market size. The surge in integration of nanotechnology in drug delivery, targeted drug deliveries, and personalized medicine for improved patient care and quality of life are gaining traction. Leading players in the global market are innovating to provide cost-effective and convenient formulations, further driving market growth.
The key regions considered for the Global Thin Film Drug Manufacturing Market study include Asia Pacific, North America, Europe, Latin America, and Middle East and Africa. North America is the dominating region in the Global Thin Film Drug Manufacturing Market. This dominance is primarily attributed to the region's advanced healthcare infrastructure, significant investment in research and development, and the presence of major pharmaceutical companies. The United States, in particular, leads in innovation and adoption of advanced drug delivery technologies, including thin film drug manufacturing. Additionally, favorable regulatory policies and substantial funding from both government and private sectors support the development and commercialization of thin film drug products. Moreover, Asia Pacific is projected to register fastest growth during to forecast period owing to rising disease prevalence, rising government initiatives for drug manufacturing in the region.
Major market player included in this report are:
Pfizer, Inc.
Novartis AG
Wolters Kluwer
Solvay
AbbVie
Sumitomo Pharma Co., Ltd
IntelGenx Corp.
NAL Pharma
ZIM Laboratories Limited
Indivior PLC
MonoSol
GSK (GlaxoSmithKline plc)
Cure Pharmaceutical Holding Corp.
Sumitomo Dainippon Pharma Co., Ltd.
Allergan plc
The detailed segments and sub-segment of the market are explained below:
By Product
Oral Thin Film
Sublingual Film
Fully Dissolving Dental/Buccal Film
Transdermal Thin Film
Others
By Disease Indication
Schizophrenia
Migraine
Opioid Dependence
Nausea & Vomiting
Others
By Distribution Channel
Hospital Pharmacies
Drug Stores
Retail Pharmacies
E-commerce
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE (Rest of Europe)
Asia Pacific
China
India
Japan
Australia
RoAPAC (Rest of Asia Pacific)
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
Saudi Arabia
South Africa
RoMEA (Rest of Middle East & Africa)
Years considered for the study are as follows:
Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032
Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.
